# AstraZeneca’s Farxiga approved by the FDA for heart failure

- Link: https://www.directorstalkinterviews.com/astrazenecas-farxiga-approved-by-the-fda-for-heart-failure/4121118137
- Published: 2023-05-09T08:13:58+01:00
- Author: Amilia Stone

AstraZeneca’s _Farxiga_ (dapagliflozin) has been approved in the US to reduce the
risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent
heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration(
FDA) was based on positive results from the DELIVER Phase III trial.^(1) _Farxiga_
was previously approved in the US for adults with HF with reduced ejection fraction(
HFrEF).

> **Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca,
> said**: “Approximately half of heart failure patients die within five years of
> diagnosis, highlighting an urgent unmet need for well-tolerated treatment options
> that can bring life-saving benefits and reduce the risk of cardiovascular death.
> The approval of _Farxiga_ in the US not only reinforces AstraZeneca’s commitment
> to reducing the burden of this complex and life-threatening disease, but will 
> help patients across the full spectrum of heart failure lead healthier lives.”

HF is a chronic, long-term condition that worsens over time^(2) and affects almost
seven million people in the US.^(3) It is also the leading cause of hospitalisation
for those over 65 years and represents a significant clinical and economic burden.
^(4) Approximately half of all HF patients have HF with mildly reduced ejection 
fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF)^(5) and these patients
are not only at greater risk of death and hospitalisations but experience an especially
high burden of symptoms and physical limitations, and a poor quality of life.^(6)

The data from the DELIVER Phase III trial, published in The New England Journal 
of Medicine_,_ showed _Farxiga_ reached a statistically significant and clinically
meaningful early reduction in the primary composite endpoint of CV death or worsening
HF in patients with HF with HFmrEF or HFpE.F^(1) The results from a pre-specified,
pooled analysis of the DAPA-HF and DELIVER Phase III trials, published in Nature
Medicine, showed that the treatment effect of _Farxiga_ on the composite endpoint
of cardiovascular death, hospitalisation for heart failure or urgent heart failure
was consistent across the left ventricular ejection fraction (LVEF)  range and established
_Farxiga_ as the first sodium-glucose cotransporter 2 (SGLT2) inhibitor to demonstrate
a mortality benefit.^(7)

_Farxiga_ is approved for the treatment of patients with type-2 diabetes (T2D), 
HFrEF and chronic kidney disease (CKD) in more than 100 countries around the world
including the US, the European Union (EU), China and Japan. It has most recently
received regulatory approvals in the EU, Great Britain, Japan and Turkey to extend
the HF indication to include patients across the full LVEF range.

Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one
of AstraZeneca’s main disease areas and is a key growth driver for the Company. 

Share on:
